Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts by unknown
Visualization,  Characterization,  and Turnover  of CD8 + 
Memory  T  Cells in Virus-infected  Hosts 
By Christine Zimmermann,* Karin Brduscha-tLiem,* 
Claudine Blaser,* Roll M. Zinkernagel,* and Hanspeter Pircher* 
From the *Institute  for Medical Microbiology and Hygiene, Department of Immunology, University of 
Freiburg, D-79104 Freiburg, Germany; and :~  Institute of Experimental Immunology, University of 
Ziirich, CH-8091 Ziirich, Switzerland 
Summary 
The cellular basis of T  cell memory is a controversial issue and progress has been hampered by 
the inability to induce and to trace long-term memory T  cells specific for a defined antigen in 
vivo. By using the murine model of lymphocytic choriomeningitis virus (LCMV) infection and 
an adoptive transfer system with CD8 § T  cells from transgenic mice expressing an LCMV-spe- 
cific T  cell receptor, a population of authentic memory T  cells specific for LCMV was gener- 
ated and analyzed in vivo. The transferred transgenic T  cells that have expanded (1,000-fold) 
and then  decreased (10-fold)  in LCMV-infected  C57BL/6  recipient mice exhibited the fol- 
lowing characteristics: they were (a) of larger average cell size than their naive counterparts but 
smaller than day 8  effector cells;  (b)  heterogeneous with respect to expression of cell surface 
"memory" markers; and (c) directly cytolytic when isolated from recipient spleens. The time- 
dependent proliferative activity of these LCMV-specific memory T  cells was analyzed in the 
recipients by bromodeoxyuridine labeling experiments in vivo. The experiments revealed that 
LCMV-specific CD8 + memory T  cells can persist in LCMV-immune mice for extended peri- 
ods of time (>2 mo) in the absence of cell division; the memory population as a whole sur- 
vived beyond 11 too. 
I 
mmunized individuals are able to mount more rapid and 
more effective B and T  cell responses, a phenomenon as- 
cribed  to  immunological  memory.  Operationally,  T  cells 
can be subdivided into naive, effector, and memory subsets. 
Naive  T  cells  are  resting cells  that  have not  encountered 
antigen after their release from the thymus, whereas effec- 
tor  T  cells  are  activated  cells  able  to  perform specialized 
functions with high efficiency and without further differen- 
tiation.  Although  it is well established that immunological 
T  cell memory exists,  memory T  cells  are poorly defined. 
In functional terms, T  cell memory can be characterized by 
an increased frequency of antigen-reactive cells,  produced 
by antigen-driven clonal expansion (1-3). Memory T  cells 
appear to be qualitatively different from naive T  cells  (4- 
10).  Memory  CD4 +  T  cells  have  less  stringent  require- 
ments  for  activation  than  naive  T  cells  (11-15),  secrete 
more complex patterns of cytokines (16-19),  and are more 
effective at  helping  B  cells  switch  antibody  isotype  (20). 
However, most of these studies have been performed with 
T  cells  activated  in  vitro  as  substitutes  for  true  memory 
cells. Memory T  cells have also been defined with cell sur- 
face markers that are induced or lost upon activation. How- 
ever, many of these  changes may reflect activation rather 
than  memory  (21);  moreover,  at  least  some  of  these 
changes are reversible (22,  23). 
Many examples have demonstrated that immunological 
memory  persists  for  many  years  (24).  The  mechanisms, 
however, that are responsible for maintenance of memory 
T  cell function  are not understood.  Memory T  cells  may 
either be specialized,  long-lived cells  (25-27)  or,  alterna- 
tively, their production is continuously stimulated by per- 
sistent (28,  29)  or cross-reactive (30)  antigen.  This focuses 
interest on the proliferative activity of memory T  cells of a 
defined  antigen  specificity in  immunized hosts.  Such  ex- 
periments have been performed with  memory-phenotype 
T  cells  with  undefined  antigen  specificity  (31),  but  have 
not yet been done with authentic memory T  cells with de- 
fined antigen specificity. Studies in the B cell compartment 
have revealed that memory B  cells  specific for the protein 
PE  can  persist in  PE-primed  mice  in  the  spleen  for ex- 
tended periods without cell division (32). 
Here,  we  have  used  an  adoptive  transfer  system with 
CD8 + T cells from TCR transgenic mice to generate a pop- 
ulation of authentic memory T cells specific for a defined anti- 
gen.  The transferred transgenic  CD8 + T  cells  expressed a 
TCR specific for the glycoprotein peptide aa33-41 derived 
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that  is  presented  by  H-2D  b  MHC  molecules.  Without 
LCMV  infection, adoptively transferred transgenic T  cells 
were virtually undetectable in the recipient mice, however, 
upon  activation  with  LCMV,  the  transgenic  T  cells  ex- 
panded vigorously during the acute phase of the infection 
and  then  gave  rise to  a  long-lived population of antigen- 
experienced T  cells, which  could be identified with  anti- 
bodies  specific  for  the  transgenic  TCR.  Thus,  this  ap- 
proach  provided  the  means  to  examine  surface  markers, 
functional  activity,  and  turnover  of the  LCMV-specific 
memory T  cells in LCMV-immune mice. 
Materials and Methods 
Mice.  C57BL/6 (B6) mice were obtained from the Institut flir 
Zuchthygiene, University of Zfirich or from Harlan Winkelmann 
(Borchen, Germany) and were used as recipient mice at 8-12 wk 
of age. The P14 TCR transgenic mice (line 318)  have been de- 
scribed previously (33) and were backcrossed onto the B6 back- 
ground to prevent rejection of the TCR transgenic T  cells after 
adoptive transfer into B6 mice. 
Virus.  The LCMV-WE used in this study was originally ob- 
tained from Dr. Lehmann-Grube (Heinrich-Pette-Institut, Ham- 
burg, Germany). It was propagated on L929 fibroblast cells and 
quantified in a virus plaque assay as described (34). Mice were in- 
fected intravenously with 200 PFU of LCMV-WE. 
Adoptive Transfer of TCR Transgenic T Cells.  Sex-matched spleen 
cells (10 6)  from naive transgenic mice containing 5-10%  CD8 + 
TCR. Vc~2+/V[38 + cells were injected intravenously in a volume 
of 0.5  ml medium without  FCS into normal nonirradiated B6 
mice.  3  d  after transfer, mice  were  infected with  LCMV.  For 
continuous bromodeoxyuridine (BrdU)-labeling experiments, trans- 
genic T cells were injected into thymectomized B6 mice 3 wk af- 
ter thymectomy (35). 
Flow Cytometry.  For detection of transgenic T  cells in B6 re- 
cipient mice,  spleen cells or PBL  were  incubated on  ice  with 
FITC-labeled anti-CD8  (Becton  Dickinson  &  Co.,  Mountain 
View,  CA),  PE-labeled anti-TCR  Vc~2, and biotinylated anti- 
TCR V[38 (both from PharMingen,  San Diego, CA) mAb fol- 
lowed  by  Tricolor-streptavidin  (Caltag,  South  San  Francisco, 
CA).  For the  detection of memory markers,  cells were  stained 
with FITC-labeled anti-CD8, PE-labeled anti-TCR V0c2 and bi- 
otinylated  anti-CD62L,  CD44,  CD45RB  (16A),  CD49d  or 
CDllb  mAb  (PharMingen),  followed by Tricolor-streptavidin. 
Staining of PBL was performed in PBS containing 2% FCS, 0.1% 
NaN  3,  and  10  U/ml heparin (Liquemin; Hoffmann-La Roche, 
Basel).  PBL were analyzed after lysis of red blood cells using the 
FACS|  Solution (Becton Dickinson & Co.) according to 
the  instructions  of the  manufacturer.  BrdU  staining was  per- 
formed  as  described  previously  by  Tough  and  Sprent  (31). 
Briefly,  after surface  staining with  biotinylated anti-CD8,  PE- 
anti-TCR V~x2, and Tricolor-streptavidin, spleen cells were fixed 
with  95%  ethanol.  After permeabilization in  1%  paraformalde- 
hyde and 0.01% Tween 20, cells were treated with DNase I (50 
Kunitz U/ml; Sigma Chemical Co., St. Louis, MO), washed, and 
incubated with FITC-conjugated anti-BrdU antibodies (Becton 
1Abbreviations used is'. this paper: B6, C57BL/6 mice; BrdU, bromodeoxy- 
uridine; FSC, forward light scatter; LCMV, lymphocytic choriomeningi- 
tis virus; VLA-4, very late antigen 4. 
Dickinson & Co.). Cells were analyzed on a FACScan  |  flow cy- 
tometer (Becton Dickinson & Co.). 
Cytotoxicity Assay.  Ex vivo cytolytic  activity of spleen cells was 
determined  in  a  SlCr-release assay  as  described  (36).  Briefly, 
spleen cells were prepared in MEM  containing 2%  FCS. EL-4 
(H-2  b)  target  cells  were  coated with  the  LCMV  glycoprotein 
peptide 33-41  (KAVYNFATM) at a concentration of 1 ~M, and 
were labeled with 250  p,  Ci SlCr for 2  h  at 37~  on a rocking 
platform. Spleen cells were incubated in 96-well round-bottom 
plates with 104 target cells at ratios of 100:1, 33:1,  11:1, 3.7:1, 
1.2:1,  and  0.4:1  in  200  p,1. After a  5-h  incubation period at 
37~  70 ILl supernatants were harvested and counted. The ratio 
of transgenic T  cells to target cells was calculated using data from 
flow cytometric analysis of an aliquot of the responder cells. 
BrdU Treatment.  Mice were given drinking water containing 
BrdU (Sigma Chemical Co.) at 0.8 mg/ml for the indicated peri- 
ods of time. Drinking water containing BrdU was protected from 
light and changed every 2 d. 
Results 
Adoptively  Transferred  T  Cells from  TCR  Transgenic Mice 
Expand  Vigorously after LCMV Infection.  To  follow directly 
the kinetics ofLCMV-specific CD8 + T  cells after an LCMV 
infection,  106  spleen cells from transgenic mice containing 
5-10%  transgenic  TCR +  (Ve12/V[38)  T  cells were  adop- 
tively transferred into normal, nonirradiated B6 mice. With- 
out LCMV infection, transgenic T  cells were virtually un- 
detectable in the  recipient mice by flow cytometry when 
tested immediately (Fig. 1,  b and c) or 50 d  (not shown) af- 
ter cell transfer. After LCMV infection, transgenic T  cells 
expanded vigorously, and on day 8 after infection, 70-80% 
of total CD8 +  T  cells in the recipient mice expressed the 
transgenic TCR  (Figs.  1 d and 2  a). Titration experiments 
with spleen cells containing graded numbers  of transgenic 
T  cells established that transfer of 3  ￿  104 to 3  ￿  10  s TCR 
transgenic  T  cells  yielded comparable  numbers  of trans- 
genic T  cells after LCMV infection in the recipient mice (not 
shown).  The  kinetics of the  transferred transgenic  T  cells 
was followed in PBL of four individual mice for 49 wk af- 
ter infection. After the acute phase of the infection, the fre- 
quency oftransgenic T  cells in PBL declined ~10-fold and 
reached a plateau 6-7 wk after infection (Fig. 2  b).  It is in- 
teresting to note that the frequency of transgenic T  cells in- 
creased about twofold in the late (>20 wk) memory phase 
when the mice were >30 wk of age. This might be due to 
a  decreased  generation  of host  T  cells  in  the  thymus  of 
older  recipient  mice,  resulting  in  lower  dilution  of the 
memory T  cell pool by newly generated naive T  cells. 
To assess the actual number of cells involved in this ex- 
pansion and decline, mice transferred with the transgenic T 
cells were killed both in the acute and the memory phases, 
and the number of transgenic T  cells in the spleen was de- 
termined (Fig. 2 c). The percentage ofVIx2+/V[38 + cells in 
the  CD8  subset of splenocytes and PBL was  equivalent in 
the same individual (not shown). The transferred transgenic 
T  cells (5-10  ￿  104) expanded about 1,000-fold during the 
acute phase of the infection, yielding 3-6  X  107 transgenic 
T  cells in the spleen. In the memory phase  (6-13 wk after 
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Figure  1.  Flow cytometric detection of TCK transgenic T  cells.  Spleen cells of the mice indicated were stained with antibodies specific for CD8, 
TCK V~x2, and TCR V[38. The dot plots show expression ofTCK V~2 and V[38 gated for CD8 + T  cells. Cells were taken from TCR transgenic mice 
(a), normal B6 mice (b), B6 mice that had received 105 TCK transgenic T  cells (c), and from B6 recipients ofTC1K transgenic T  cells 8 (d) or 50 d (e) after 
LCMV infection. Without LCMV infection, transgenic T cells were undetectable in the recipient mice by flow cytometry when tested immediately (c) or 
50 d (not shown) after cell transfer. The large numbers in the quadrants indicate the percentage ofTCIK Va2+/V[38 + cells of CD8 + T  cells; the small 
numbers indicate the percentage oftransgenic T  cells of total splenocytes. 
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Figure  2.  Kinetics of transgenic T  cells in vivo after LCMV infection. 
B6 mice that received 10  s TC1K transgenic T  cells on day -3  were in- 
fected with LCMV on day 0.  Flow cytometric analysis,  as described in 
1369  Zimmermann et al. 
infection), the numbers oftransgenic T  cells (2-6  ￿  106 per 
spleen)  were  decreased  "-d0-fold,  when  compared  to  the 
acute  phase,  and  were  increased  ~100-fold  when  com- 
pared to the initial input of naive transgenic T  cells. 
Characterization of Transgenic Memory T Cells.  The preced- 
ing data demonstrated that the transgenic T  cells in LCMV- 
infected  recipient  mice  were  produced  by antigen-driven 
clonal  expansion  from a  few naive  transgenic  T  cells that 
were  undetectable  in  the  recipient  mice  without  LCMV 
infection.  It is therefore  proper  to  refer to  this  transgenic 
population  in LCMV-immune  mice as authentic  antigen- 
experienced memory T  cells. The cell size oftransgenic naive, 
effector, and memory T  cells was compared by flow cytom- 
etry using forward light scatter (FSC). Electronic gates were 
used to display the FSC oftransgenic  (1K2 =  Vo~2+/V[38 +) 
versus  nontransgenic  (R3  =  Vc~2-/V[38-)  CD8 +  T  cells 
analyzed in  the  same  FACS |  sample.  In uninfected  trans- 
genic mice, the FSC of CD8 + T  cells expressing the trans- 
genic  TCR  did  not  differ from  CD8 +  T  cells  expressing 
endogenous  TC1K (Fig.  3  a). During the  acute LCMV in- 
fection,  CD8 +  T  cells were  blast-sized  with  an  increased 
FSC (Fig. 3  b). In LCMV memory mice, CD8 + T  cells ex- 
pressing  the  transgenic  TCR  exhibited  an  increased  FSC 
when compared to CD8 + cells expressing endogenous TCR 
(Fig. 3 c, mean FSC, 506 versus 468). Thus, the average cell 
size of LCMV  memory CD8 +  T  cells in LCMV-immune 
mice was larger than that of naive T  cells (mean FSC,  506 
Fig. 1, was performed on PBL at the indicated time points after infection. 
The percentage of transgenic (Vcx2+/V~8  +) T  cells of CD8 §  (a) and of 
total PBL (b) of four individual mice is shown. In c, the absolute numbers 
of transgenic CD8+Vec2+/V[~8 +  cells  in  the spleen of individual mice 
killed at the indicated time points after infection are depicted. The num- 
bers were  determined by  multiplying the  percentage  of CD8+VoL2+/ 
V[38 + cells by the total number ofspteen cells. The number of transgenic 
donor cells homing to the spleen after in vivo transfer was considered to 
be 20% of the injected inoculum (48). a  TCR tg (naive) 
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Figure  3.  Cell size of transgenic naive,  effector, 
and  memory  T  cells  measured  by  forward  light 
scatter (FSC).  B6 recipients  of TCt( transgenic  T 
cells were infected  with LCMV.  PBL from naive 
transgenic  mice (a)  and from recipient  mice 8  (b) 
and 50 d (c) after infection were stained with CD8-, 
TCR.  V~2-,  and  TCI(  VI38-specific  antibodies. 
The FSC histograms (right) are of R3-gated endog- 
enous  CD8+V~2-/V[~8 -  and  of R2-gated  trans- 
genic  CD8+V~x2+/VI38  + cells￿9 The mean FSC of 
the gated population  is shown.  The t(2/P,3  gates 
are indicated on the Vo~2/V[38 dot plots (left) which 
were gated  for CD8 + cells. Identical  results were 
obtained when splenocytes were analyzed (data not 
shown). 
versus 465),  but smaller than that  of effector T  cells during 
the  acute  phase  of the  infection  (mean  FSC,  506  versus 
557).  It is important to stress, however, that the FSC histo- 
grams of the different cell populations  overlapped,  indicat- 
ing that cells of similar size can be found in the naive, effec- 
tor, and memory T  cell pool. 
The adoptive transfer model described here provided an 
excellent opportunity  to examine cell surface markers  asso- 
ciated with T  cell memory on authentic,  in vivo-generated 
memory  T  cells.  PBL  from  noninfected  TCR  transgenic 
mice  (naive)  and from  recipients  of transgenic  T  cells at  8 
(effector) and >50  d  (memory)  after LCMV  infection were 
stained  with mAbs  specific for CD62L  (L-selectin),  CD44 
(Pgp-1),  CDllb  (Mac-l),  CD49d  (very late antigen [VLA- 
4]),  and  CD45RB.  The  dot  plots  shown  in  Fig.  4  are  of 
gated CD8 + cells and display the expression of these mark- 
ers both on transgenic  (V~2 +) and on host-derived (VoL2-) 
CD8 + T  cells for comparison.  The lymphocyte homing re- 
ceptor  L-selectin  (CD62L)  was  expressed  on  most  naive 
transgenic T  cells but was absent on effector T  cells in acute 
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Figure 4.  Surface  phenotype of transgenic naive, effector, and memory 
T  cells. B6  recipients of TCR  transgenic T  cells were  infected with 
LCMV. PBL from naive TCR transgenic mice (left)  and from infected re- 
cipient mice 8 (middle) and >50 d (right) after infection were stained with 
mAbs specific for CD62L (L-selectin), CD44 (Pgp-1), CD49d (VLA-4), 
CD11b (Mac-l), CD45RB,  CD8, and TCR VIx2. The dot plots shown 
are of gated CD8 + cells. 
infection. It is interesting to note that 20--30% oftransgenic 
memory T  cells were CD62L high demonstrating that antigen- 
experienced T  cells like naive cells may express a CD62L high 
phenotype in vivo. Expression of CD44 was upregulated to 
the same extent in most, but not all, of the transgenic effec- 
tor and memory T  cells. CD1 lb was expressed on 50-70% 
of effector T  cells but on only a few (2-5%) transgenic mem- 
ory T  cells. Like CD44,  CD49d was upregulated in trans- 
genie effector and memory T  cells. However, in contrast to 
CD44, CD49d expression on memory T  cells was threefold 
lower  than  that  of effector  cells  (mean  fluorescence,  201 
versus 642)  but threefold higher when  compared to naive 
T  cells (mean fluorescence, 201  versus 61).  CD45  isoform 
expression is frequently used to define memory T  cells (37). 
CD45RB  expression was decreased on effector cells com- 
pared to naive T  cells (mean fluorescence, 586 versus 1,207), 
whereas most memory cells, like naive T  cells, expressed a 
CD45R.B high phenotype (mean fluorescence, 1,197). 
The cell size analysis and the expression pattern of adhe- 
sion molecules described above indicated that some of the 
memory T  cells displayed an activated phenotype. We there- 
fore asked whether transgenic CD8 + memory T  cells were 
directly cytolytic when  tested  on  target cells coated with 
the LCMV  glycoprotein peptide 33-41  recognized by the 
transgenic TCR.  Transgenic  T  cells from naive and from 
acutely infected animals were  included in  these  assays for 
comparison.  The  data  showed  that  in  contrast  to  naive 
cells,  ex  vivo-isolated  transgenic  memory  T  cells  lysed 
LCMV peptide-coated target cells in a short-term, 5 h SlCr- 
release  assay  (Fig.  5).  The  direct  comparison  with  day  8 
transgenic effector cells revealed a 10-20-fold reduced lytic 
activity on  a  cell per cell basis, suggesting that  the  CD8 + 
memory T  cell pool in LCMV-immune  mice is heteroge- 
neous and contains only a few cells that display instant cy- 
tolytic activities. Spleen cells from LCMV memory (>day 
50)  B6  mice  that  did not  receive transgenic  T  cells were 
not cytolytic in this type of assay (data not shown), indicat- 
ing that the LCMV-specific lysis was due to the transgenic 
memory T  cell population. 
Turnover of Memory  T  Cells in LCMVoimmune  Mice.  The 
experiments of the preceding sections indicate that  trans- 
genie memory T  cells persisted in LCMV-immune mice for 
prolonged periods (Fig. 2). To analyze the proliferation of 
transgenic T  cells in these hosts, the DNA precursor, BrdU 
was administered in the drinking water.  Incorporation and 
decay of this label was analyzed in transgenic and nontrans- 
genic CD8 § T  cel/s. 
In  the  first  set  of experiments,  B6  recipients  of TCR. 
transgenic  T  cells were  infected  with  LCMV  and  given 
BrdU water for the first week after infection. Then, BrdU 
was  chased by transferring the  mice  to  normal water;  the 
rate of decay of labeled cells was monitored (Fig. 6  a). On 
day  1  after chase,  88-95%  of transgenic  (V~x2  +)  and  66- 
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Figure 5.  Ex vivo CTL activ- 
ity of transgenic naive, effector, 
and  memory  T  cells. Ex  vivo 
isolated splenocytes from  naive 
TCR  transgenic mice  (open cir- 
cles) and  from  B6  recipients of 
TCR  transgenic  T  cells  8  d 
(closed circles) and  13  wk  (closed 
quadrants) after LCMV infection 
were tested on EL-4 target cells 
coated with  the  LCMV  glyco- 
protein  peptide 33-41 in a 5-h 
51Cr-release assay. Nonspecific 
lysis  of  uncoated  EL-4  target 
cells was <8%. The percent spe- 
cific lysis is plotted  against the 
transgenic T cell to target cell ra- 
tio  which  was  determined  by 
flow cytometry of an aliquot of 
the input splenocytes. 
1371  Zimmermann et al. 77%  of the  nontransgenic  (Vot2-)  CD8 +  T  cells  in  the 
spleen  were  labeled  with  BrdU.  The  host-derived  non- 
transgenic CD8 + T  cells have receptors of unknown speci- 
ficity and most  of them were  stimulated unspecifically by 
the  inflammatory process,  since the  frequency of LCMV- 
specific CTL precursors within this population was below 
1/20  (data not shown).  The percentage  ofBrdU §  cells in 
this nontransgenic CD8 § subset declined rapidly during the 
first 2  wk and remained constant thereafter  (11-15%).  In 
marked  contrast,  the  proportion  of  labeled  transgenic 
CD8 + T  cells decayed very slowly during the 8-wk period 
of observation,  8  wk  after  chase,  65%  of the  transgenic 
memory T  cells still carried the BrdU label. The plots dis- 
playing TCP.  Va2  and BrdU staining intensities gated  on 
CD8 + T  cells showed that the BrdU + and the BrdU-  cells 
appeared as discrete populations within the transgenic Vc~2 + 
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subset,  and  that  the  mean  fluorescence  intensity  of  the 
BrdU label of the transgenic memory cells did not substan- 
tially  decrease  within  the  observation  period  (Fig.  6  b). 
These data suggest that the transgenic memory T  cell pool is 
heterogeneous,  consisting of dividing (BrdU-)  and of virtu- 
ally nondividing (BrdU +) cells. 
In the  second  set  of experiments,  the  kinetics of BrdU 
incorporation upon continuous labeling was examined. For 
these  experiments,  thymectomized B6  recipients  of TCR. 
transgenic  T  cells  were  infected  with  LCMV  and  given 
BrdU water at 4  (Fig. 7  a) and 17 wk (Fig. 7  b) after infec- 
tion.  Three points emerged from these data.  First, the  ex- 
periments with short-term  (4-wk)  and long-term (17-wk) 
LCMV-immune  mice yielded similar results. Second, trans- 
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Figure 6.  Decay of BrdU label in transgenic and nontransgenic CD8 + 
T cells in the spleen after LCMV infection. B6 recipients ofTCP, trans- 
genic T  cells were infected with LCMV (arrow) and given BrdU water 
(thick line) for 8 d. Then, BrdU was chased by transferring mice to normal 
water. (a) The percent BrdU  + cells of the transgenic (Va2 +, dosed &des) 
and nontransgenic  (Va2-, open circles) splenic CD8 + T  cells was deter- 
mined using three-color  staining at the indicated weeks after chase. Dots 
represent values from individual recipient mice. (b) Representative stain- 
ing patterns ofBrdU-labeled CD8 + T cells 1 and 8 wk after chase. Spleen 
cells were first stained for CD8 and TCR Va2 followed by nuclear stain- 
ing for BrdU incorporation.  The BrdU/Va2 plots are of gated CD8 + 
cells and the numbers in the quadrants indicate percentage ofCD8 + cells. 
b  mice 17 wk after LCMV infection 
100 
80 
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Figure  7.  Continuous BrdU labehng of transgenic and nontransgenic 
CD8 + T cells in the spleen in LCMV-immune mice. Thymectomized B6 
recipients  of TCR  transgenic T  cells were  infected  with  LCMV  and 
given BrdU for the entire duration of the experiment starting 4 (a) and 17 
wk (b) after infection. The percent BrdU  + cells of the transgenic (Va2 +, 
closed circles) and nontransgenic  (V~2-, open circles) splenic CD8 + T cells 
was determined at the indicated weeks of continuous labehng. Dots rep- 
resent values from individual recipient mice. The BrdU/V(x2 plots show 
a representative staining pattern ofCD8 + T cells 2 and 5 wk after contin- 
uous BrdU labeling. 
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netic  similar  to  the  entire  pool  of host-derived  (Vcl2-) 
CD8 + T  cells. Third, 30--40% oftransgenic memory T  cells 
excluded  BrdU  over a  7-wk  period,  implying that  these 
cells were nondividing. 
Discussion 
The present report examines, for the first time, a popula- 
tion containing 95-99% of memory CD8 + T  cells induced 
by a defined antigen in vivo with respect to surface markers 
and cell cychng. This was made possible by LCMV-induced 
clonal expansion of the TCR transgenic T  cells in an adop- 
tive  transfer system.  The  overall  kinetics  of >1,000-fold 
expansion of transgenic T  cells followed by a 10-fold con- 
traction  agrees  well  with  the  kinetics  of LCMV-specific 
CD8 + T  cells in normal B6 mice after LCMV infection, as 
determined by CTL precursor frequency analysis (3).  It is 
noteworthy  that spleen  cells from day 8  LCMV-immune 
recipients ofTCR transgenic T  cells also exhibited cytolytic 
activity specific for the LCMV nucleoprotein peptide NP 
394-408, indicating that the introduction  of the transgenic 
T  cells did not preclude the normal host response (data not 
shown). The frequency oftransgenic TCtk + cells per CD8 + 
cell dropped from the peak of the response to the memory 
phase only by a factor of two, and afterwards remained re- 
markably stable. This result fits well with the idea that the 
clonal burst of virus-specific T  cells during the acute phase 
of the infection primarily determines the size of the mem- 
ory T cell compartment (26). It further implies that the T  cell 
pool, after an infection, is heavily biased with cells specific 
for the most recent pathogen, with little  change in the T 
cell repertoire between the acute infection and the memory 
state. 
TCR  transgenic  CD4 +  T  cells  specific  for  a  chicken 
ovalbumin  peptide  have  been  previously  used  in  similar 
adoptive transfer experiments by Kearuey et al. (38). In these 
latter experiments, the transferred ovalbumin-specific T  cells 
expanded upon immunization with the  antigenic peptide, 
and at the peak of the response 3% of CD4 §  T  cells  ex- 
pressed the transgenic TCR.  The extent of clonal expan- 
sion observed in our transfer model is far greater since 70% 
of CD8 § T  cells were of transgenic origin during the acute 
phase of LCMV infection. It is conceivable that the differ- 
ent types of antigen  challenge---synthetic peptide in  CFA 
versus infectious virus--were responsible for the  different 
degrees of clonal  expansion  observed in  these  two  trans- 
genic transfer models. However, it is noteworthy that the 
extent of clonal expansion observed in the LCMV model 
was  similar  to  the  level  of expansion  of antigen-specific 
CD4 + T  cell "clonotypes" in draining lymph nodes of nor- 
mal mice primed with pigeon cytochrome c (39). 
The  adoptive  transfer model  described  here  allowed  a 
critical evaluation of the suitability of cell surface markers 
widely used to define memory T cells. The expression of  these 
markers appears to be highly complex (Fig. 4). Three major 
points emerged from this data. First, 20-30% of transgenic 
memory T  cells  expressed, like naive T  cells,  a CD62L  high 
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phenotype,  indicating  that  expression of the  lymph node 
homing receptor CD62L  (L-selectin)  on T  cells  is revers- 
ible in vivo. This observation agrees well with two recent 
studies demonstrating CTL precursors specific for LCMV, 
influenza  A  and  Sendai  virus  in  the  pool  of CD62L  high 
CD8 +  T  cells  (40,  41).  Second,  CD44  was  increased  in 
transgenic effector and memory T  cells to the same extent. 
In  contrast,  expression  of CD49d  (VLA-4)  was  high  on 
transgenic  effector  T  cells,  intermediate  on  memory  T 
cells, and low on naive T  cells. Thus, expression of CD49d 
correlated well with the three different T  cell populations 
in our system. CD49 binds to vascular cell adhesion mole- 
cule  1 and is important for recruitment of lymphocytes to 
sites  of inflammation  (42-45).  Third,  CD11b  and CD45 
isoform expression has been used to discriminate naive and 
memory T  cells  (37,  46).  Our  results  revealed that  most 
CD8 §  memory  T  cells  generated  in  our  model  were 
CDllb-  and  CD45R]3 high, like  naive  T  cells.  Thus,  ex- 
pression of these markers on CD8 + T  cells appears to cor- 
relate more closely with cell  activation than with memory. 
It is possible that the few CDllb + and CD45RB l~  cells in 
the memory T  cell pool correspond to memory T  cells re- 
cently  reactivated  by  persistent  or  cross-reactive  antigen. 
Our data on CD1 lb expression on memory CD8 + cells are 
in contrast to the results reported by McFarland et al.  (46) 
which  showed that elimination of CD11b + cells  from re- 
sponder spleen  cells  of LCMV-immune  mice abolished a 
secondary LCMV-specific CTL response in vitro. The rea- 
son for this discrepancy is not clear. In our system, the pro- 
liferative in vitro response of the transgenic memory T  cell 
population  containing  CD11 +  cells  was  not  enhanced 
when  compared to CD11-  naive TCR  transgenic T  cells 
(data not shown). 
There is much controversy as to whether the more rapid 
and more effective secondary immune response in an anti- 
gen-primed host is simply due to the increased frequency 
of antigen-reactive T  cells  or to a distinct characteristic of 
memory T  cells  (21,  47).  The finding  that the  transgenic 
memory T  cell population exhibited cytolytic activities dem- 
onstrates  that,  in  contrast  to  naive  T  cells,  certain  CD8 § 
memory T  cells  are  rapidly  capable of interfering with  a 
second  viral  challenge  by lysing virus-infected  cells.  The 
frequency of these  "cytolytic" memory T  cells within the 
total memory population is not known. The comparison of 
the lytic activities on a cell per cell basis  revealed that the 
frequency of these  directly  cytolytic CD8 §  T  cells  drops 
10-20-fold  when  passing from the  acute  to  the  memory 
phase  (Fig.  5).  It will be important to determine whether 
these cytolytic memory T  cells are dependent on continu- 
ous TCR-mediated stimulation by persistent antigen. 
The main conclusion to be drawn from BrdU labeling 
experiments is that CD8 + LCMV-specific memory T  cells 
turn over at a low rate in LCMV-immune mice. The much 
more rapid decline of the BrdU label in the bystander-acti- 
vated CD8 + T  cell pool suggests that the average life span 
of these  cells  is considerably shorter than that of the  anti- 
gen-induced  transgenic  T  cells.  Tough  and  Sprent  (31) 
have recently examined, by BrdU labeling experiments, the turnover of memory T  cells defined by surface markers and 
have reported no or only a slow decay in the percent label- 
ing of memory-phenotype CD8 + T  cells  in the chase pe- 
riod.  Our results  using bona fide memory T  cells  confirm 
this finding. We did not, however, observe a similar marked 
switch  from  BrdU  high to  BrdU  l~  cells  during  the  8-wk 
chase  period,  indicating  that,  in contrast to memory-phe- 
notype CD8 §  T  cells,  a sizable portion of LCMV-specific 
memory T  cells  was not cycling in LCMV-immune mice. 
In the  continuous labeling  experiments,  BrdU incorpora- 
tion by the  transgenic  memory T  cells  was  similar  to  the 
BrdU labeling data  of CD62L  I~  CD8 + T  cells  in the  ex- 
periments of Tough and Sprent (3l), but differed from their 
results  obtained  with  memory-phenotype  CD4 +  T  cells 
and CD44  high and CD45RB  int CD8 + T  cells,  which exhib- 
ited  more  rapid  BrdU  incorporation  kinetics.  These  dis- 
crepancies may be due to the fact that the memory markers 
available to date correlate primarily with ceil activation and 
do not discriminate between recently activated T  cells  and 
memory T  cells. 
Our data  demonstrate  that about half of the  transgenic, 
LCMV-specific memory T  cells persisted in LCMV-immune 
mice for 5-7  wk in  the  absence  of cell  division,  whereas 
the  other half of the  memory T  cells  incorporated BrdU, 
thus  indicating  ceil  division.  The present  report  does  not 
address  the issue  of whether persistence  of viral antigen is 
responsible for this low level of proliferation;  this question 
remains to be answered in this system. It is, however, note- 
worthy that the kinetics of the BrdU labeling oftransgenic 
memory T  cells were virtually identical when started either 
4  or  17  wk  after priming  with  LCMV  (Fig.  7,  a  and  b). 
This result is different from that obtained in similar experi- 
ments analyzing the proliferative activity of memory B cells 
specific for PE (32).  When BrdU was given to mice 4 wk 
after immunization with PE and continued for 5 wk,  62% 
of PE-specific  memory B  cells  were  labeled.  In  contrast, 
when BrdU was given to mice  10 wk after priming,  only 
12-18% of PE-specific memory B cells incorporated BrdU. 
It is conceivable that the time-dependent  decrease of pro- 
liferation  of PE-specific  memory  B  cells  in  PE-primed 
mice,  which is in contrast to the result obtained here with 
memory T  cells  in  LCMV-infected  mice,  reflects  persis- 
tence of antigen; this is more likely to occur after priming 
with an infectious virus than with protein antigens. 
The present analysis ofclonally expanded transgenic T  cells 
in  recipient  mice  permitted  the  definition  of cell  surface 
markers and turnover of virus-specific CD8 + memory T  cells 
in vivo. Because  of massive expansion  of the transgenic  T 
cells seen, the system will simplify further cellular and mo- 
lecular analysis of effector and memory T  cells  in immune 
hosts. 
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